These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31481582)

  • 1. Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer.
    Ramos N; Baquero-Buitrago J; Ben Youss Gironda Z; Wadghiri YZ; Reiner T; Boada FE; Carlucci G
    J Nucl Med; 2020 Mar; 61(3):437-442. PubMed ID: 31481582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Biological Evaluation of Novel
    Song X; Gan Q; Zhang X; Zhang J
    Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and Evaluation of [
    Xiao D; Gan Q; Duan X; Wang Q; Jiang Y; Han P; Zhang J
    Mol Pharm; 2023 Sep; 20(9):4528-4536. PubMed ID: 37661815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging.
    Huang CH; Khan P; Xu S; Cohen J; Georgakis GV; Turkman N
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and evaluation of
    Gan Q; Song X; Zhang X; Zhang J
    Eur J Med Chem; 2020 Feb; 188():112032. PubMed ID: 31926467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [
    Elmi A; Makvandi M; Weng CC; Hou C; Clark AS; Mach RH; Mankoff DA
    Clin Cancer Res; 2019 May; 25(10):3063-3073. PubMed ID: 30692100
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Xu D; Zhuang R; You L; Guo Z; Wang X; Peng C; Zhang D; Zhang P; Wu H; Pan W; Zhang X
    Nucl Med Biol; 2018 Apr; 59():48-55. PubMed ID: 29466767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gallium-68 Labeling of the Cyclin-Dependent Kinase 4/6 Inhibitors as Positron Emission Tomography Radiotracers for Tumor Imaging.
    Liu C; Yang Z; Liu M; Wang X; Song S; Xu X; Yang Z
    ACS Omega; 2021 Nov; 6(47):32253-32261. PubMed ID: 34870045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High in-vivo stability in preclinical and first-in-human experiments with [
    Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging.
    Tang L; Peng C; Tang B; Li Z; Wang X; Li J; Gao F; Huang L; Xu D; Zhang P; Zhuang R; Su X; Chen X; Zhang X
    J Nucl Med; 2018 Sep; 59(9):1386-1391. PubMed ID: 29653973
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Gao F; Peng C; Zhuang R; Guo Z; Liu H; Huang L; Li H; Xu D; Wen X; Fang J; Zhang X
    Nucl Med Biol; 2019; 72-73():62-69. PubMed ID: 31330414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
    Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET imaging of a
    Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
    Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Ma G; Liu C; Lian W; Zhang Y; Yuan H; Zhang Y; Song S; Yang Z
    Ann Nucl Med; 2021 May; 35(5):600-607. PubMed ID: 33689138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-Step
    Huang H; Li K; Lv G; Liu G; Zhao X; Liu Q; Wang S; Li X; Qiu L; Lin J
    Contrast Media Mol Imaging; 2018; 2018():5362329. PubMed ID: 29692688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
    Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
    Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.